The problem of cancer dormancy: Understanding the basic mechanisms and identifying therapeutic opportunities

Cell Cycle

Volumn 5, Issue 16, 2006, Pages 1740-1743

  Aguirre Ghiso, Julio A ^a,b  

^a UNIVERSITY AT ALBANY   (United States)

^b STATE UNIVERSITY OF NEW YORK   (United States)

Author keywords

Angiogenesis; Metastasis; Quiescence; Signal transduction; Stem cells

Indexed keywords

CYTOKERATIN 18; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; INTEGRIN; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE P38; MONOCLONAL ANTIBODY; MYC PROTEIN; STRESS ACTIVATED PROTEIN KINASE; UROKINASE RECEPTOR; VASCULOTROPIN INHIBITOR;

CANCER CELL; CANCER GROWTH; CANCER RECURRENCE; CANCER STAGING; CANCER STEM CELL; CELL PROLIFERATION; DIAGNOSTIC IMAGING; DORMANCY; GENE INACTIVATION; GENE MUTATION; GENETIC TRANSFORMATION; HYPEROXIA; HYPOXIA; MOLECULAR GENETICS; NONHUMAN; PROTEIN EXPRESSION; RECEPTOR DOWN REGULATION; REVIEW;

ANIMALIA;

EID: 33748931283     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.5.16.3165     Document Type: Review

References (52)

1. Pantel K, Brakenhoff RH. Dissecting the metastatic cascade. Nat Rev Cancer 2004; 4:448-56.
2. Schmidt-Kittler O, Ragg T, Daskalakis A, Granzow M, Ahr A, Blankenstein TJ, Kaufmann M, Diebold J, Arnholdt H, Muller P, Bischoff J, Harich D, Schlimok G, Riethmuller G, Eils R, Klein CA. From latent disseminated cells to overt metastasis: Genetic analysis of systemic breast cancer progression. Proc Natl Acad Sci USA 2003; 100:7737-42.
3. Riethmuller G, Klein CA. Early cancer cell dissemination and late metastatic relapse: Clinical reflections and biological approaches to the dormancy problem in patients. Semin Cancer Biol 2001; 11:307-11.
4. Demicheli R. Tumour dormancy: Findings and hypotheses from clinical research on breast cancer. Semin Cancer Biol 2001; 11:297-306.
5. Demicheli R, Miceli R, Moliterni A, Zambetti M, Hrushesky WJ, Retsky MW, Valagussa P, Bonadonna G. Breast cancer recurrence dynamics following adjuvant CMF is consistent with tumor dormancy and mastectomy-driven acceleration of the metastatic process. Ann Oncol 2005; 16:1449-57.
6. Roepman P, Wessels LF, Kettelarij N, Kemmeren P, Miles AJ, Lijnzaad P, Tilanus MG, Koole R, Hordijk GJ, van der Vliet PC, Reinders MJ, Slootweg PJ, Holstege FC. An expression profile for diagnosis of lymph node metastases from primary head and neck squamous cell carcinomas. Nat Genet 2005; 37:182-6.
7. Akervall J. Gene profiling in squamous cell carcinoma of the head and neck. Cancer Metastasis Rev 2005; 24:87-94.
8. Schardt JA, Meyer M, Hartmann CH, Schubert F, Schmidt-Kittler O, Fuhrmann C, Polzer B, Petronio M, Eils R, Klein CA. Genomic analysis of single cytokeratin-positive cells from bone marrow reveals early mutational events in breast cancer. Cancer Cell 2005; 8:227-39.
9. Aguirre-Ghiso JA, Ossowski L, Rosenbaum SK. Green fluorescent protein tagging of extracellular signal-regulated kinase and p38 pathways reveals novel dynamics of pathway activation during primary and metastatic growth. Cancer Res 2004; 64:7336-45.
10. Chambers AF, Naumov GN, Varghese HJ, Nadkarni KV, MacDonald IC, Groom AC. Critical steps in hematogenous metastasis: An overview. Surg Oncol Clin N Am 2001; 10:243-55, vii.
11. Uhr JW, Marches R. Dormancy in a model of murine B cell lymphoma. Semin Cancer Biol 2001; 11:277-83.
12. Townson JL, Chambers AF. Dormancy of solitary metastatic cells. Cell Cycle 2006; In Press.
13. Marches R, Scheuermann RH, Uhr J. Cancer dormancy from mice to man: A review. Cell Cycle 2006; In Press.
14. Indraccolo S, Favaro E, Amadori A. Dormant tumors awaken by a short-term angiogenic burst: The spike hypothesis. Cell Cycle 2006; In Press.
15. White DE, Rayment JH, Muller W. Addressing the role of cell adhesion in tumor cell dormancy. Cell Cycle 2006; In Press.
16. Laufs S, Schumacher J, Allgayer H. Urokinase-receptor (u-PAR)-an essential player in multiple games of cancer: A review on its role in tumor progression, invasion, metastasis, proliferation/dormancy, clinical outcome and minimal residual disease. Cell Cycle 2006; In Press.
17. Naumov GN, Akslen LA, Folkman J. Role of angiogenesis in human tumor dormancy: Animal models of the angiogenic switch. Cell Cycle 2006; In Press.
18. Klein CA, Hölzel D. Systemic cancer progression and tumor dormancy: Mathematical models meet single cell genomics. Cell Cycle 2006; In Press.
19. Ranganathan AC, Adam AP, Aguirre-Ghiso JA. Opposing roles of mitogenic and stress signaling pathways in the induction of cancer dormancy. Cell Cycle 2006; In Press.
20. Felsher DW. Tumor dormancy: Death and resurrection of cancer as seen through transgenic mouse models. Cell Cycle 2006; In Press.
21. Aguirre-Ghiso JA, Kovalski K, Ossowski L. Tumor dormancy induced by downregulation of urokinase receptor in human carcinoma involves integrin and MAPK signaling. J Cell Biol 1999; 147:89-104.
22. Naumov GN, MacDonald IC, Weinmeister PM, Kerkvliet N, Nadkarni KV, Wilson SM, Morris VL, Groom AC, Chambers AF. Persistence of solitary mammary carcinoma cells in a secondary site: A possible contributor to dormancy. Cancer Res 2002; 62:2162-8.
23. Naumov GN, Bender E, Zurakowski D, Kang SY, Sampson D, Flynn E, Watnick RS, Straume O, Akslen LA, Folkman J, Almog N. A model of human tumor dormancy: An angiogenic switch from the nonangiogenic phenotype. J Natl Cancer Inst 2006; 98:316-25.
24. Naumov GN, Townson JL, MacDonald IC, Wilson SM, Bramwell VH, Groom AC, Chambers AF. Ineffectiveness of doxorubicin treatment on solitary dormant mammary carcinoma cells or late-developing metastases. Breast Cancer Res Treat 2003; 82:199-206.
25. Ranganathan AC, Zhang L, Adam AP, Aguirre-Ghiso JA. Functional coupling of p38-induced upregulation of BiP and activation of RNA-dependent protein kinase-like endoplasmic reticulum kinase to drug resistance of dormant carcinoma cells. Cancer Res 2006; 66:1702-11.
26. Shachaf CM, Felsher DW. Tumor dormancy and MYC inactivation: Pushing cancer to the brink of normalcy. Cancer Res 2005; 65:4471-4.
27. Meng S, Tripathy D, Frenkel EP, Shete S, Naftalis EZ, Huth JF, Beitsch PD, Leitch M, Hoover S, Euhus D, Haley B, Morrison L, Fleming TP, Herlyn D, Terstappen LW, Fehm T, Tucker TF, Lane N, Wang J, Uhr JW. Circulating tumor cells in patients with breast cancer dormancy. Clin Cancer Res 2004; 10:8152-62.
28. Allgayer H, Heiss MM, Riesenberg R, Grutzner KU, Tarabichi A, Babic R, Schildberg FW. Urokinase plasminogen activator receptor (uPA-R): One potential characteristic of metastatic phenotypes in minimal residual tumor disease. Cancer Res 1997; 57:1394-9.
29. Heiss MM, Allgayer H, Gruetzner KU, Funke I, Babic R, Jauch KW, Schildberg FW. Individual development and uPA-receptor expression of disseminated tumour cells in bone marrow: A reference to early systemic disease in solid cancer. Nat Med 1995; 1:1035-9.
30. Yu W, Kim J, Ossowski L. Reduction in surface urokinase receptor forces malignant cells into a protracted state of dormancy. J Cell Biol 1997; 137:767-77.
31. Aguirre-Ghiso JA, Estrada Y, Liu D, Ossowski L. ERK(MAPK) activity as a determinant of tumor growth and dormancy; regulation by p38(SAPK). Cancer Res 2003; 63:1684-95.
32. Shachaf CM, Kopelman AM, Arvanitis C, Karlsson A, Beer S, Mandl S, Bachmann MH, Borowsky AD, Ruebner B, Cardiff RD, Yang Q, Bishop JM, Contag CH, Felsher DW. MYC inactivation uncovers pluripotent differentiation and tumour dormancy in hepatocellular cancer. Nature 2004; 431:1112-7.
33. Salm SN, Burger PE, Coetzee S, Goto K, Moscatelli D, Wilson EL. TGF-{beta} maintains dormancy of prostatic stem cells in the proximal region of ducts. J Cell Biol 2005; 170:81-90.
34. Talpaz M, Estrov Z, Kantarjian H, Ku S, Foteh A, Kurzrock R. Persistence of dormant leukemic progenitors during interferon-induced remission in chronic myelogenous leukemia. Analysis by polymerase chain reaction of individual colonies. J Clin Invest 1994; 94:1383-9.
35. Pantel K, Otte M. Occult micrometastasis: Enrichment, identification and characterization of single disseminated tumour cells. Semin Cancer Biol 2001; 11:327-37.
36. Wong CW, Lee A, Shientag L, Yu J, Dong Y, Kao G, Al-Mehdi AB, Bernhard EJ, Muschel RJ. Apoptosis: An early event in metastatic inefficiency. Cancer Res 2001; 61:333-8.
37. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000; 100:57-70.
38. Muraoka-Cook RS, Kurokawa H, Koh Y, Forbes JT, Roebuck LR, Barcellos-Hoff MH, Moody SE, Chodosh LA, Arteaga CL. Conditional overexpression of active transforming growth factor beta1 in vivo accelerates metastases of transgenic mammary tumors. Cancer Res 2004; 64:9002-11.
39. White DE, Kurpios NA, Zuo D, Hassell JA, Blaess S, Mueller U, Muller WJ. Targeted disruption of beta1-integrin in a transgenic mouse model of human breast cancer reveals an essential role in mammary tumor induction. Cancer Cell 2004; 6:159-70.
40. Tilli MT, Furth PA. Conditional mouse models demonstrate oncogene-dependent differences in tumor maintenance and recurrence. Breast Cancer Res 2003; 5:202-5.
41. Naumov GN, MacDonald IC, Chambers AF, Groom AC. Solitary cancer cells as a possible source of tumour dormancy? Semin Cancer Biol 2001; 11:271-6.
42. Folkman J. Role of angiogenesis in tumor growth and metastasis. Semin Oncol 2002; 29:15-8.
43. Folkman J, Hanahan D. Switch to the angiogenic phenotype during tumorigenesis. Princess Takamatsu Symp 1991; 22:339-47.
44. Weaver VM, Petersen OW, Wang F, Larabell CA, Briand P, Damsky C, Bissell MJ. Reversion of the malignant phenotype of human breast cells in three-dimensional culture and in vivo by integrin blocking antibodies. J Cell Biol 1997; 137:231-45.
45. Liu D, Aguirre-Ghiso J, Estrada Y, Ossowski L. EGFR is a transducer of the urokinase receptor initiated signal that is required for in vivo growth of a human carcinoma. Cancer Cell 2002; 1:445-57.
46. Aguirre-Ghiso JA, Liu D, Mignatti A, Kovalski K, Ossowski L. Urokinase receptor and fibronectin regulate the ERK(MAPK) to p38(MAPK) activity ratios that determine carcinoma cell proliferation or dormancy in vivo. Mol Biol Cell 2001; 12:863-79.
47. Watnick RS, Cheng YN, Rangarajan A, Ince TA, Weinberg RA. Ras modulates Myc activity to repress thrombospondin-1 expression and increase tumor angiogenesis. Cancer Cell 2003; 3:219-31.
48. Marches R, Hsueh R, Uhr JW. Cancer dormancy and cell signaling: Induction of p21(waf1) initiated by membrane IgM engagement increases survival of B lymphoma cells. Proc Natl Acad Sci USA 1999; 96:8711-5.
49. Erber R, Thurnher A, Katsen AD, Groth G, Kerger H, Hammes HP, Menger MD, Ullrich A, Vajkoczy P. Combined inhibition of VEGF and PDGF signaling enforces tumor vessel regression by interfering with pericyte-mediated endothelial cell survival mechanisms. Faseb J 2004; 18:338-40.
50. Sebolt-Leopold JS, Dudley DT, Herrera R, Van Becelaere K, Wiland A, Gowan RC, Tecle H, Barrett SD, Bridges A, Przybranowski S, Leopold WR, Saltiel AR. Blockade of the MAP kinase pathway suppresses growth of colon tumors in vivo. Nat Med 1999; 5:810-6.
51. Kwak EL, Sordella R, Bell DW, Godin-Heymann N, Okimoto RA, Brannigan BW, Harris PL, Driscoll DR, Fidias P, Lynch TJ, Rabindran SK, McGinnis JP, Wissner A, Sharma SV, Isselbacher KJ, Settleman J, Haber DA. Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib. Proc Natl Acad Sci USA 2005; 102:7665-70.
52. Mendelsohn J. Targeting the epidermal growth factor receptor for cancer therapy. J Clin Oncol 2002; 20:1S-13S.